Diabetes Challenge 2018-06-05T10:02:41+00:00

Protomer Technologies Takes Top Prize in 2018 Diabetes Innovation Challenge

Revolutionary “smart” drug could prevent hypoglycemia in people with diabetes

BOSTON, May 22, 2018 (GLOBE NEWSWIRE) — Protomer Technologies of Pasadena, CA, will receive $50,000 in cash and up to $150,000 of in-kind support as the winner of the 2018 Diabetes Innovation Challenge. The Challenge is a world-wide competition run by T1D Exchange to identify, nurture and fast-track innovative scientific and clinical solutions for diabetes.

Protomer Technologies’ pipeline glucose-responsive glucagon is expected to sense low sugar levels and automatically activate to restore blood sugar levels to prevent potentially life-threatening hypoglycemia (a dangerous drop in blood sugar levels).

“Every person with type 1 diabetes who takes insulin lives in fear of hypoglycemia, and for some, it means they never quite achieve optimal insulin levels,” said Protomer Technologies Founder and CEO Alborz Mahdavi, PhD. “The visibility and exposure of winning the Diabetes Innovation Challenge, along with the first-place prize, will be invaluable in our efforts to bring this smart-drug technology to people with diabetes as soon as possible.”

Winners were announced following presentations from ten finalists during a public Pitch Off yesterday at the Royal Sonesta in Cambridge, MA.

T1D Exchange is a nonprofit research organization dedicated to accelerating treatments and improving care for people with type 1 diabetes (T1D). The organization and its sponsors launched the Diabetes Innovation Challenge in 2016 to connect innovators in the diabetes space, diabetes industry leaders and individuals with the disease.

The Second-Place winner is New York start-up Bonbouton, which has designed a smart shoe insole to continuously monitor people with diabetes for foot ulcers that can lead to amputations. Bonbouton will receive $25,000 and up to $50,000 of in-kind support.

The Third-Place winner is Boston-area based Cam Med for an ultra-thin, bandage-like patch pump that has the potential to greatly improve medication compliance and lower costs, especially for patients with challenging medication regimens that involve frequent injections.

Two People’s Choice Winners of online public voting were also named. Autonomous_ID of Ottawa, Canada, is working to develop a self-contained biometric identification and monitoring technology called Smart Sole Salvation to support self-care management of diabetes. SciDogma Research of Bengaluru, Karnataka, India, is developing an E-pancreas with a closed loop delivery system.

“We are thrilled to support the advancement of these exciting solutions and the potential they hold for the 30 million people living with diabetes,” said T1D Exchange President and CEO Dana Ball. “Previous awardees have used our support to move from a promising idea to the brink of approval. We expect no less from this year’s winners.”

This year’s lead sponsors were The Leona M. and Harry B. Helmsley Charitable Trust and JDRF. Other sponsors included the American Diabetes Association, Eli Lilly and Company and Lexicon Pharmaceuticals, Inc.

“JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat type 1 diabetes and its complications,” said Julia Greenstein, PhD, vice-president of research strategy at JDRF and one of the judges of this year’s event. “We are thrilled with the potential each one of these proposals has to make a difference for people with type 1 diabetes.”

“When my wife was diagnosed with gestational diabetes, I came to understand just how many people with diabetes could benefit from this technology,” said Bonbouton Co-Founder and CEO Le Linh. “The support of the Diabetes Innovation Challenge, and the people I have met through this program, will help us put our idea to work to keep people with diabetes healthy and prevent thousands of foot amputations each year.”

“Although wearable insulin pumps have gotten smaller, there has been a need to make them more effective, more comfortable and less obtrusive to improve both insulin control and the quality of life for people with type 1 diabetes,” said Cam Med CEO Laurence Alberts. “You can’t put a price tag on what it means to the advancement of the Evopump patch pump to have the support of T1D Exchange and the Diabetes Innovation Challenge.”

In all, 60 proposals from 17 countries were submitted across four categories: automated insulin devices; diagnostics; therapeutics; and technology design/disease management.

“We are already seeing progress in the type 1 diabetes space as a result of the support the Diabetes Innovation Challenge provided to the 2016 winners,” said David Panzirer, a trustee of the Helmsley Charitable Trust and one of the judges of this year’s event. “This outstanding event advances diabetes solutions and exemplifies the innovative thinking that Helmsley is committed to supporting.”

“In just two short years we have seen the Diabetes Innovation Challenge grow to become a showcase for new ideas and an international driver of progress,” said Jay Mohr, president and CEO of Dirigo Therapeutics and a member of the Board of T1D Exchange. “More importantly, it has provided pivotal resources and financial support to transform these ideas into better care for people living with diabetes.”

About Type 1 Diabetes
Studies show that at least 1.25 million Americans are living with type 1 diabetes, including more than 200,000 young people under the age of 20. Alarmingly, there was a 21 percent increase in the prevalence of type one diabetes among young people from 2001-2009, with 40,000 new cases diagnosed each year. At the current rate, the number of people with type 1 diabetes is expected to grow to more than 5 million people in the U.S. by 2050.

About T1D Exchange
T1D Exchange is a nonprofit research organization dedicated to accelerating therapies and improving care for people affected by type 1 diabetes. T1D Exchange actively supports discovery and innovation—particularly at its earliest stages. At the same time, the organization asserts that evidence gathered in the “real world” can help bridge the gap between discovery in research settings and impact in people’s lives.

The T1D Exchange model uses cutting-edge research tools, methods and programs to gather biological samples from people living with type 1 diabetes, as well as evidence from their real-world experiences. The goal is to link patient samples, data and insight to all stages of research and development, advancing the development of therapies and better care for everyone affected by type 1 diabetes.

Contacts 
For more information about the 2018 Diabetes Innovation Challenge or T1D Exchange, please contact John Gillespie at (314) 708-9090 Jgillespie@T1DExchange.org or Rebecca Parkes, Chief Advancement Officer at (617) 892-6100 RParkes@T1DExchange.org.

Please note: In a release issued under the same headline earlier today by T1D Exchange, the name of Protomer Technologies Founder and CEO  Alborz Mahdavi and Bonbouton CEO Linh Le were misspelled. We regret the errors. 

Finalists Announced for 2018 Diabetes Innovation Challenge
Winners of $250,000 in Cash and In-Kind Prizes to be Announced at Live Event in Boston May 21, 2018. 

BOSTON, April 24, 2018 (GLOBE NEWSWIRE) — T1D Exchange, a nonprofit patient-centered research organization dedicated to accelerating novel treatments to improve the lives of people with type 1 diabetes (T1D), today announced that 10 academic research teams and early stage companies have been named as finalists in the 2018 Diabetes Innovation Challenge, a world-wide competition to identify, nurture and advance innovative scientific and clinical solutions for diabetes.

The announcement comes after proposals from 30 semi-finalists were reviewed by a panel of experts. Additionally, nearly 500 votes have been cast to date for a separate People’s Choice Award. In all, 60 proposals were received from 17 countries.

The opportunity for the community to review and vote for the People’s Choice Award recipient is unique to the Diabetes Innovation Challenge, and a centerpiece of the T1D Exchange mission to connect patients to researchers and innovators. Those who wish to review descriptions of the entries and cast their vote for their favorite proposal are encouraged to go to the Vote Now link. Voting ends May 19, 2018.

The 2018 Diabetes Innovation Challenge is presented by T1D Exchange with the generous support of lead sponsors, The Leona M. and Harry B. Helmsley Charitable Trust and JDRF. Major sponsors include the American Diabetes Association, Eli Lilly and Company and Lexicon Pharmaceuticals, Inc.

“The quality of this year’s entries, and especially the finalists, is truly remarkable,” said Jay Mohr, President and CEO of Dirigo Therapeutics and a member of the Board of T1D Exchange. “We are excited to provide these innovators with the opportunity to advance their ideas and showcase their efforts to address the needs of those living with diabetes.”

Studies show that at least 1.25 million Americans are living with type 1 diabetes, including more than 200,000 young people under the age of 20. Alarmingly, there was a 21 percent increase in the prevalence of type one diabetes among young people from 2001-2009, with 40,000 new cases diagnosed each year. At the current rate, the number of people with type one diabetes is expected to grow to more than 5 million people in the U.S. by 2050.

“These findings underscore the need for innovative solutions to improve the health and quality of life of the growing number of people living with diabetes,” added Mohr.

Each finalist will make a formal, in-person presentation of their proposal to a select panel of judges at a public event on May 21, 2018, at the Royal Sonesta Boston in Cambridge, MA. Winners will be announced immediately following the presentations.

A total of $250,000 in cash and additional in-kind support for concept/product development will be awarded among the first, second, and third prize winners.

The finalists include proposals in four categories that are critical to advancing the care of people with diabetes including:

Automated Insulin Devices (Artificial Pancreas) and related components such as novel glucose sensing, insulin delivery systems, and cellular therapy delivery technologies

  • AP Advance: An autonomous and discreet diabetes management system mimicking a healthy pancreas
  • CAM MED LLC: An ultra-thin, flexible, bandage-like patch pump that delivers multiple drugs at minimal cost
  • MicromedicsInc.: A portable bio-artificial pancreas using microfabrication technology to mimic the pancreas

Diagnostics such as novel low-cost tests for research and screening; early diagnosis and prevention; autoantibodies, C- peptide, or other markers such as beta cell death and risk of diabetic complications

  • Bonbouton: Early detection of signals that can lead to foot ulcers and amputations in diabetic patients
  • VOTIS Subdermal Imaging Technologies, Ltd.:  Pathology of the diabetic foot

Therapeutics including smart insulins, glucagons, immune-modulating therapies, beta cell regeneration and treatments for diabetic complications

  • Protomer Technologies Inc.: Weekly injectable glucagon that senses low blood sugar and automatically activates in the body
  • Ridgeline Therapeutics: Oral medication to treat Type 2 diabetes by selectively shrinking fat deposits
  • University of Southern California: Device to maintain oxygen levels in the eye and prevent blindness

Technology Design/Disease Management solutions for new and disruptive approaches to the use of information and communication technologies to support diabetes management

  • Capillary Biomedical, Inc.: A soft, multi-port, kink-proof cannula and comfortable, reliable infusion
  • Integrated Medical Sensors: The world’s smallest wireless user-insertable 30-day glucose sensor

Members of the general public can register for the event here.

About T1D Exchange
T1D Exchange is an innovative nonprofit research organization founded on the belief that people affected by type 1 diabetes need better treatments and better care faster. T1D Exchange puts the community of people living with type 1 diabetes at the center of research that will meaningfully impact their lives. The T1D Exchange model offers researchers access to a large patient community, aggregated clinical, biological, and patient-reported data, and a rich collection of biological samples. The goal is to leverage T1D Exchange’s expertise and resources, connect key stakeholders, and link patient insight to all stages of research and development aimed at improving care and quality of life for everyone affected by type 1 diabetes.

T1D Exchange fosters collaboration and offers a wide-array of resources to the type 1 diabetes community including a Clinic Network, a Clinic Registry, a robust Biobank, and the GLU patient community with more than 21,000 members.

Contacts 
For more information about the 2018 Diabetes Innovation Challenge or T1D Exchange, please contact John Gillespie at (314) 708-9090 Jgillespie@T1DExchange.org or Rebecca Parkes, Chief Advancement Officer at (617) 892-6100 RParkes@T1DExchange.org.

Please note: In a release issued under the same headline earlier today by T1D Exchange, the name of Protomer Technologies Founder and CEO  Alborz Mahdavi was misspelled. We regret the error. 


Monday, May 21, 2018, 2:00 PM – 7:00 PM
Royal Sonesta Boston, Cambridge, MA 02142

You are invited to attend this year’s live pitch-off event to identify and accelerate transformational advancements in diabetes research and care. As an attendee you will have the opportunity to preview poster presentations from the 30 semifinalists, followed by a pitch-off event showcasing the finalists. A People’s Choice award will also be given to the recipient of the most votes during the public voting period.

Please join us this May as we award up to $250,000 in cash and in-kind services to the top three innovative ideas and solutions that could change the quality of life for millions of people who are living with diabetes.

Agenda

2:00-2:30PM Registration & Reception including 30 finalists poster presentation

2:30-5:30PM Pitch-Off Event showcasing the 10 Finalists

5:30-7:00PM Cocktail Reception and Announcement of Winnersnt of Winners

GENEROUSLY SUPPORTED BY THE FOLLOWING SPONSORS:

Lead Sponsors

Platinum Sponsor

Silver Sponsors

In-kind Services will be provided by

Platinum Sponsor

Silver sponsors

General sponsors

And a Thank You to our Individual Sponsors

  • Team Carly Rocks Foundation
  • The Claire Friedlander Family Foundation
  • The Geoffrey S. Rehnert Family Charitable Fund

We would also like to thank our awareness partners

  • Accelerace
  • ATTD
  • Close Concerns
  • Diabetes Technology Society
  • Dreamit Health
  • Interface Health
  • GIANT Health
  • Healthbox
  • HubX LifeSciences
  • M2D2
  • MassChallenge PULSE
  • Mass. Life Sciences Ctr.
  • MassBio
  • Mass Device
  • MaRS Centre for Impact Investing
  • MedTech Innovator
  • Sansum Diabetes Research Institute
  • TMC Innovation Institute

SPONSORSHIP DETAILS:

Want to be involved in this exciting event? There are many ways you or your organization can participate in the Diabetes Innovation Challenge.

Read the Executive Brief

Learn about Sponsorship Opportunities

Review Sponsorship Levels

For more information, contact challenge.